IDO signaling—Tregs induced by IDO-expressing leukemic DCs impair leukemia-specific CTL (103).Increased IDO activity—lower CR rates and shorter OS in AML (103–105).Blocking of IDO—effective immune response in AML in vitro (103–106). This evidence concerns the gene IDO1 and acute myeloid leukemia.